Squamous cell carcinoma - Karsinoma Sél Skuamosa
☆ Dina hasil Stiftung Warentest 2022 ti Jerman, kapuasan konsumen sareng ModelDerm ngan ukur langkung handap tibatan konsultasi telemedicine anu mayar.
Squamous cell carcinoma well differentiated ― Keratosis actinic padeukeut dititénan.
References
Squamous cell carcinoma (SCC) mangrupa kanker kulit paling umum kadua di Amérika Serikat, sanggeus basal cell carcinoma. Biasana dimimitian tina lesi precancerous anu disebut actinic keratosis , sareng tiasa nyebar ka bagian awak anu sanés. Anu ngabalukarkeun utama nyaéta paparan sinar ultraviolét (UV) tina panonpoé, anu akumulasi kana waktosna. Perawatan biasana ngalibatkeun panyabutan bedah, khususna pikeun SCC dina sirah sareng beuheung. Terapi radiasi mangrupikeun pilihan pikeun pasien sepuh atanapi anu henteu tiasa dioperasi. Immunosuppression ningkatkeun résiko SCC. Sanajan langka, SCC bisa nyebarkeun, utamana dina penderita sistim imun lemah. Pamariksaan rutin sareng panyalindungan panonpoé penting pikeun anu ngagaduhan SCC.
Squamous cell carcinoma of the skin or cutaneous squamous cell carcinoma is the second most common form of skin cancer in the United States, behind basal cell carcinoma. Squamous cell carcinoma has precursor lesions called actinic keratosis, exhibits tumor progression and has the potential to metastasize in the body. Ultraviolet (UV) solar radiation is the primary risk factor in the development of cutaneous squamous cell carcinoma and the cumulative exposure received over a lifetime plays a major part in the development of this cancer. Surgical excision is the primary treatment modality for cutaneous squamous cell carcinoma, with Mohs micrographic surgery being the preferred excisional technique for squamous cell carcinoma of the head and neck, and in other areas of high risk or squamous cell carcinoma with high-risk characteristics. Radiation therapy is reserved for squamous cell carcinoma in older patients or those who will not tolerate surgery, or when it has not been possible to obtain clear margins surgically. Adjuvant radiotherapy is commonly after surgical treatment in very high tumors. Immunosuppression significantly increases the risk of squamous cell carcinoma over the course of an individual’s life. Metastasis is uncommon for squamous cell carcinomas arising in areas of chronic sun exposure, but it can take place, and the risk is increased in immunosuppressed patients. Patients with cutaneous squamous cell carcinoma should be examined regularly and remember to use measures to protect from UV damage.
Squamous cell carcinoma of the skin or cutaneous squamous cell carcinoma is the second most common form of skin cancer in the United States, behind basal cell carcinoma. Squamous cell carcinoma has precursor lesions called actinic keratosis, exhibits tumor progression and has the potential to metastasize in the body. Ultraviolet (UV) solar radiation is the primary risk factor in the development of cutaneous squamous cell carcinoma and the cumulative exposure received over a lifetime plays a major part in the development of this cancer. Surgical excision is the primary treatment modality for cutaneous squamous cell carcinoma, with Mohs micrographic surgery being the preferred excisional technique for squamous cell carcinoma of the head and neck, and in other areas of high risk or squamous cell carcinoma with high-risk characteristics. Radiation therapy is reserved for squamous cell carcinoma in older patients or those who will not tolerate surgery, or when it has not been possible to obtain clear margins surgically. Adjuvant radiotherapy is commonly after surgical treatment in very high tumors. Immunosuppression significantly increases the risk of squamous cell carcinoma over the course of an individual’s life. Metastasis is uncommon for squamous cell carcinomas arising in areas of chronic sun exposure, but it can take place, and the risk is increased in immunosuppressed patients. Patients with cutaneous squamous cell carcinoma should be examined regularly and remember to use measures to protect from UV damage.
Cutaneous squamous cell carcinoma (CSCC) mangrupikeun kanker anu paling umum kadua di jalma, sareng jumlahna naék. Sanajan CSCC biasana nembongkeun paripolah klinis benign, éta bisa nyebarkeun duanana lokal jeung bagian séjén awak. Élmuwan geus ngaidentifikasi jalur husus aub dina ngembangkeun CSCC, ngarah kana perlakuan anyar. Jumlah mutasi anu luhur sareng résiko ningkat dina penderita immunosuppressed parantos nyababkeun ngembangkeun immunotherapy. Tinjauan ieu ningali akar genetik CSCC sareng pangobatan pangénggalna nargétkeun molekul khusus sareng sistem imun.
Cutaneous squamous cell carcinoma (CSCC) is the second most frequent cancer in humans and its incidence continues to rise. Although CSCC usually display a benign clinical behavior, it can be both locally invasive and metastatic. The signaling pathways involved in CSCC development have given rise to targetable molecules in recent decades. In addition, the high mutational burden and increased risk of CSCC in patients under immunosuppression were part of the rationale for developing the immunotherapy for CSCC that has changed the therapeutic landscape. This review focuses on the molecular basis of CSCC and the current biology-based approaches of targeted therapies and immune checkpoint inhibitors
Cutaneous squamous cell carcinoma (CSCC) is the second most frequent cancer in humans and its incidence continues to rise. Although CSCC usually display a benign clinical behavior, it can be both locally invasive and metastatic. The signaling pathways involved in CSCC development have given rise to targetable molecules in recent decades. In addition, the high mutational burden and increased risk of CSCC in patients under immunosuppression were part of the rationale for developing the immunotherapy for CSCC that has changed the therapeutic landscape. This review focuses on the molecular basis of CSCC and the current biology-based approaches of targeted therapies and immune checkpoint inhibitors
○ Diagnosis sareng Perawatan
#Dermoscopy
#Skin biopsy